In addition, LPH could potentially serve as a potential candidate biomarker for CRC risk stratification or a druggable target for CRC treatment, as several other circulating proteins associated with CRC risk have been implemented for these purposes [17,18,19,20]. The gene discussed is LCT; the disease is colorectal carcinoma.